Home Management Cachexia Bone Marrow Dyslipidemia Pipeline Contact Us


[The proposed human trials are based on the results described in seven issued and three pending U.S. and international patent applications.]

Candidate & Indication
Developmental Stage
Pre-clinical & Animal Toxicology
Human Phase 1 Human Toxicology
Human Phase 2 Clinical
I. rPLAP for treating cancer cachexia and protecting bone marrow function.
Exit after Phase 1 or move to Phase 2
II. rPLAP + chemotherapy for cancer treatments in Phase II trial examining the expected outcomes:
1. Enhance cancer treatments,
2. Reduce muscle wasting,
3. Reduce loss of body weight, and
4. Protect bone marrow
Exit after Phase 2 trial
III. PLAP with or without a statin for the treatment of dyslipidemia